ReviewAmerican journal of cardiovascular disease2021
Adverse effects of conjugated linoleic acids supplementation on circulating lipoprotein (a) levels in overweight and obese individuals: results of a systematic review and meta-analysis of randomized controlled trials.
Review in American journal of cardiovascular disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- Differential effects of bariatric surgery and lifestyle interventions on plasma levels of Lp(a) and fatty acids.Lipids in health and disease · 2022Trial
- The Safety of Nebulized Conjugated Linoleic Acid for COVID-19 Respiratory Tract Infections.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conjugated Linoleic Acids (CLA) may have beneficial effects on the prevention of atherosclerosis, but their net effects on circulating levels of lipoprotein (a) [Lp (a)] are unclear. The present study aimed to systematically review and analyze the Randomized Clinical Trials (RCTs) assessing the effects of CLA on circulating Lp (a) concentrations. A literature search of SCOPUS, PubMed-Medline, ISI, Web of Science, and Cochrane library databases was conducted for the relevant RCTs investigating the effects of CLA supplementation on circulating Lp (a) levels, which had been published up to 20 August 2020. Weighted Mean Difference (WMD) and 95% Confidence Intervals (CI) were reported as the summary statistics. Statistical analysis were done with Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ). Totally, six studies with 13 treatment arms including 752 subjects were included in the meta-analysis. The results showed a significant increase in circulating Lp (a) levels after CLA supplementation (WMD: 16.68 mg/L, 95% CI: 5.43-27.93; P=0.004) with no evidence of heterogeneity across the studies. In the subgroup analysis, a more significant elevation of Lp (a) levels was observed in the trials lasting for six months or more (WMD: 21.61 mg/L, 95% CI: 9.85-33.37, P<0.001) as well as in those with a supplementation dosage of ≥3.5 g/d (WMD: 26.13 mg/L, 95% CI: 7.02-45.24, P=0.007). These findings were sensitive to one study. It can be concluded that CLA supplementation with a dose of ≥3.5 g/d over a six-month period might significantly increase the circulating Lp (a) concentrations.
Indexed as
Identifiers
33815928PMC8012289W3144975159What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.